Sponsor or institution
Clinical trials and research at Excyte Biopharma Ltd
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Excyte Biopharma Ltd that are recruiting, in China. By phase: Phase 1 (3), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| YK012 for moderate-to-severe lupus (SLE) | Phase 1/2 | Beijing, Beijing Municipality | Recruiting | Jun 8, 2025 |
| Evaluating YK012 for treating primary membranous nephropathy | Phase 1 | Beijing, Beijing Municipality | Recruiting | May 21, 2025 |
| Treatment of B-cell Acute Lymphoblastic Leukemia with YK012 | Phase 1/2 | Guangzhou, Guangdong and 11 other locations | Recruiting | Aug 30, 2024 |
| Testing YKST02 for patients with relapsed or refractory multiple myeloma | Phase 1 | Beijing, Beijing Municipality and 11 other locations | Recruiting | Aug 28, 2024 |
| Evaluating YK012 for treating relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1 | Beijing, Beijing Municipality | Recruiting | Aug 22, 2024 |
All recruiting trials (5)
-
YK012 for moderate-to-severe lupus (SLE)
This study will test YK012 in adults with moderate-to-severe lupus to see if it is safe and can lower disease activity.
-
Evaluating YK012 for treating primary membranous nephropathy
This study is testing a new treatment called YK012 to see if it can help people with primary membranous nephropathy feel better and how safe it is to use.
-
Treatment of B-cell Acute Lymphoblastic Leukemia with YK012
This study is testing a new treatment called YK012 to see if it can safely help people with B-cell acute lymphoblastic leukemia fight their cancer.
-
Testing YKST02 for patients with relapsed or refractory multiple myeloma
This study is testing a new treatment called YKST02 to see if it can help people with relapsed or hard-to-treat multiple myeloma by boosting their immune system.
-
Evaluating YK012 for treating relapsed or refractory B-cell non-Hodgkin lymphoma
This study is testing a new drug called YK012 to see if it can safely help people with relapsed or refractory B-cell non-Hodgkin lymphoma.
Quick answers
How many clinical trials run by Excyte Biopharma Ltd are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.